| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/24/2012 | WO2012065967A1 Substituted sodium-1h-pyrazole-5-olate |
| 05/24/2012 | WO2012065956A1 Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors |
| 05/24/2012 | WO2012065953A1 Substituted carbamoylcycloalkyl acetic acid derivatives as nep inhibitors |
| 05/24/2012 | WO2012065527A1 Compouds and uses as l-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof |
| 05/24/2012 | WO2012024309A3 Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer |
| 05/24/2012 | WO2012023810A3 Pharmaceutical composition for promoting angiogenesis, and method for screening for active substances for promoting angiogenesis |
| 05/24/2012 | WO2012015750A3 Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies |
| 05/24/2012 | US20120130303 Rate control during af using cellular intervention to modulate av node |
| 05/24/2012 | US20120130300 Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics |
| 05/24/2012 | US20120129932 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
| 05/24/2012 | US20120129930 Ketone compounds and compositions for cholesterol management and related uses |
| 05/24/2012 | US20120129926 Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| 05/24/2012 | US20120129917 Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| 05/24/2012 | US20120129906 Modulators of s1p receptors |
| 05/24/2012 | US20120129900 Dual-acting antihypertensive agents |
| 05/24/2012 | US20120129897 Bis heteroaryl inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | US20120129892 Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl)pyridine and their therapeutical uses |
| 05/24/2012 | US20120129886 Metalloenzyme inhibitor compounds |
| 05/24/2012 | US20120129878 Tablet |
| 05/24/2012 | US20120129876 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| 05/24/2012 | US20120129872 Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | US20120129870 Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor |
| 05/24/2012 | US20120129868 Poly (adp-ribose) polymerase (parp) inhibitors |
| 05/24/2012 | US20120129867 Inhibitors of protein kinases |
| 05/24/2012 | US20120129866 Methods for preventing or treating metabolic diseases, inflammatory diseases, autoimmune diseases, allergic diseases, central nervous system diseases, cardiovascular diseases, homeostasis-related diseases or glaucoma |
| 05/24/2012 | US20120129864 Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same |
| 05/24/2012 | US20120129863 Chymase inhibitors |
| 05/24/2012 | US20120129858 Compounds, compositions and methods comprising pyridazine sulfonamide derivatives |
| 05/24/2012 | US20120129857 Substituted sodium 1H-pyrazol-5-olate |
| 05/24/2012 | US20120129856 Compounds, compositions and methods useful for cholesterol mobilisation |
| 05/24/2012 | US20120129851 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives |
| 05/24/2012 | US20120129848 Benzo [E] [1,3] Oxazin-4-One Derivatives as Phosphoinositide 3-Kinase Inhibitors |
| 05/24/2012 | US20120129847 Compositions and methods for treating ocular edema, neovascularization and related diseases |
| 05/24/2012 | US20120129843 Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | US20120129842 Bisthiazole inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | US20120129833 Cyclic ketoenols for therapy |
| 05/24/2012 | US20120129831 Substituted 3-(1,2,4-Oxadiazol-5-yl)-5-Phenylpiperidines |
| 05/24/2012 | US20120129830 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof |
| 05/24/2012 | US20120129829 Novel indole modulators of s1p receptors |
| 05/24/2012 | US20120129818 Compositions and Methods for Treatment of Cardiovascular Disease |
| 05/24/2012 | US20120129814 Novel phosphonic acids as s1p receptor modulators |
| 05/24/2012 | US20120129813 Novel compounds as receptor modulators with therapeutic utility |
| 05/24/2012 | US20120129812 Novel thyroid hormone beta receptor agonist |
| 05/24/2012 | US20120129811 Tricyclic inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | US20120129806 Arginase inhibitors as therapeutics |
| 05/24/2012 | US20120129805 Barley and uses thereof |
| 05/24/2012 | US20120129785 Companion animal nutrition system |
| 05/24/2012 | US20120129783 Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| 05/24/2012 | US20120129776 Bioactive peptides and method of using same |
| 05/24/2012 | US20120129774 Kinin b1 receptor peptide agonists and uses thereof |
| 05/24/2012 | US20120129772 Soluble igf receptors as anti-angiogenic agents |
| 05/24/2012 | US20120129758 Muscle function enhancing peptide |
| 05/24/2012 | US20120129757 Compositions and methods for promoting vascular barrier function and treating pulonary fibrosis |
| 05/24/2012 | US20120128794 Methods and compositions for the sustained release of chromium |
| 05/24/2012 | US20120128782 Multicomponent Degradable Cationic Polymers |
| 05/24/2012 | US20120128771 Timed, pulsatile release systems |
| 05/24/2012 | US20120128768 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 05/24/2012 | US20120128767 Therapeutic calcium phosphate particles and methods of making and using same |
| 05/24/2012 | US20120128761 Lipophilic Polynucleotide Conjugates |
| 05/24/2012 | US20120128741 Modified hyaluronic acid polymer compositions and related methods |
| 05/24/2012 | US20120128740 Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
| 05/24/2012 | US20120128727 Bacterial expression of an artificial gene for the production of crm197 and its derivatives |
| 05/24/2012 | US20120128697 NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis |
| 05/24/2012 | US20120128690 Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith |
| 05/24/2012 | US20120128686 Thienopyrimidines for pharmaceutical compositions |
| 05/24/2012 | US20120128679 Human Antibodies to the Glucagon Receptor |
| 05/24/2012 | US20120128674 C3b antibodies and methods for the prevention and treatment of complement-associated disorders |
| 05/24/2012 | US20120128660 Diagnosis of restenosis in patients undergoing percutaneous coronary intervention |
| 05/24/2012 | US20120128657 Synthetic macrocyclic compounds and methods for treating cancer |
| 05/24/2012 | US20120128640 Heterocyclic compounds and expansion agents for hematopoietic stem cells |
| 05/24/2012 | US20120128638 Pharmaceutical composition for the treatment of heart diseases |
| 05/24/2012 | US20120128637 Cellular Seeding and Co-Culture of a Three Dimensional Fibroblast Construct |
| 05/24/2012 | US20120128594 Selective infarcted-tissue-targeting bacteria and use thereof |
| 05/24/2012 | US20120128582 Methods and compositions of [32p]-labeled adenine nucleotides for the treatment of atherosclerosis, vascular arterial diseases and coronary artery diseases |
| 05/24/2012 | US20120125325 The use of amlexanox in the therapy of neutrophil-driven diseases |
| 05/24/2012 | DE102010052941A1 Therapeutisches Protein Therapeutic protein |
| 05/24/2012 | DE102010044131A1 Substituiertes Natrium-1H-pyrazol-5-olat Substituted sodium-1H-pyrazol-5-olate |
| 05/24/2012 | CA2846227A1 Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers |
| 05/24/2012 | CA2818279A1 Novel indolizine derivatives, and preparation and therapeutic use thereof |
| 05/24/2012 | CA2818002A1 Substituted sodium-1h-pyrazole-5-olate |
| 05/24/2012 | CA2817542A1 Methods for enhancing oxygenation of jeopardized tissue |
| 05/24/2012 | CA2817362A1 Lipoyl compounds and their use for treating ischemic injury |
| 05/24/2012 | CA2817114A1 Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors |
| 05/24/2012 | CA2817093A1 Nampt inhibitors |
| 05/24/2012 | CA2816594A1 Nampt and rock inhibitors |
| 05/23/2012 | EP2455469A1 Nucleic acid molecule capable of binding to hmgb1, and use thereof |
| 05/23/2012 | EP2455467A1 Double-stranded oligonucleotides |
| 05/23/2012 | EP2455096A1 Oxidized protein hydrolase activity enhancer |
| 05/23/2012 | EP2455091A1 Angiogenesis-regulating composition and angiogenesis regulation method |
| 05/23/2012 | EP2455084A2 Antihypertensive composition containing a ginsenoside-enriched fraction |
| 05/23/2012 | EP2454250A1 Apoptosis signal-regulating kinase inhibitors |
| 05/23/2012 | EP2453926A2 Peptides whose uptake in cells is controllable |
| 05/23/2012 | EP2453925A2 Cyclosporin conjugates |
| 05/23/2012 | EP2453898A1 Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases |
| 05/23/2012 | EP2453897A1 Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative |
| 05/23/2012 | EP2027096B1 Substituted arylimidaz0l0ne and triaz0l0ne as inhibitors of vasopressin receptors |
| 05/23/2012 | EP1930017B1 Composition effective for prevention and treatment of adult disease |
| 05/23/2012 | EP1865976B1 Use of natriuretic peptide for treating heart failure |
| 05/23/2012 | EP1853290B1 Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates |
| 05/23/2012 | EP1446418B1 Integrin targeting compounds |